Acute Myeloid Leukemia
Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Amer Zeidan, MBBS, MHSAcute Myeloid Leukemia | December 31, 2024
Moderated by Amer M. Zeidan, MBBS, a panel discusses the critical roles of patient fitness, genetics in AML treatment.
Amer Zeidan, MBBS, MHSAcute Myeloid Leukemia | December 31, 2024
This expert panel shares insights into the latest advancements, clinical challenges in AML and more.
Amer Zeidan, MBBS, MHSAcute Myeloid Leukemia | December 31, 2024
Gain valuable insights from leading experts as they explore how targeted therapies are shaping the future of AML management.
Nichole TuckerAcute Myeloid Leukemia | December 30, 2024
Investigators looked into how intensified induction therapy impacts survival and MRD negativity in patients with AML.
Nichole TuckerAcute Myeloid Leukemia | December 30, 2024
Results from the phase I/II SAVE study in older and unfit patients with relapsed or refractory acute myeloid leukemia.
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | December 30, 2024
HMAs, either as monotherapy or in combination with venetoclax, represent the standard of care for higher-risk MDS or AML.
Advertisement
Leah LawrenceAcute Myeloid Leukemia | December 26, 2024
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
Patrick DalyAcute Myeloid Leukemia | December 23, 2024
Ziftomenib, venetoclax, and azacitadine is an close to an all-oral regimen for relapsed/refractory acute leukemias.
Patrick DalyAcute Myeloid Leukemia | December 23, 2024
The benefit of alternating venetoclax regimens was shown in patients with AML and certain AML subgroups.
Patrick DalyAcute Myeloid Leukemia | December 23, 2024
The confirmed complete response rate of ziftomenib with chemotherapy was high in patients with AML subtypes.
Patrick DalyAcute Myeloid Leukemia | December 20, 2024
Interim results suggest acceptable safety and high efficacy of CPX-351 plus ivosidenib.
Patrick DalyAcute Myeloid Leukemia | December 20, 2024
High complete response rates and low early mortality rates facilitate the majority of patients to allogeneic SCT.
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | December 18, 2024
What potential does ASTX727 have in MDS and AML treatment?
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | December 13, 2024
New research is offering new hope for these challenging case of MDS and sAML.
Melissa BadamoAcute Myeloid Leukemia | November 19, 2024
The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%.
Blood Cancer TalksBlood Cancer Talks | November 13, 2024
On this episode, Andrew Wei, MBBS, PhD, goes especially in depth regarding venetoclax plus azacitidine combination.
Andrew MorenoAcute Myeloid Leukemia | November 13, 2024
MDS-related gene mutations and number of mutations did not correlate with worse outcomes.
Melissa BadamoAcute Myeloid Leukemia | November 6, 2024
Researchers have validated a new molecular prognostic risk signature for patients with AML who received HMAs and venetoclax.
Andrew MorenoAcute Myeloid Leukemia | November 6, 2024
The phase II component of this clinical trial evaluating ziftomenib for heavily pretreated AML is in progress.
Patrick DalyAcute Myeloid Leukemia | November 12, 2024
Pivekimab sunirine showed single-agent activity across multiple doses in the treatment of patients with AML.
Advertisement
Advertisement
Editorial Board